DEA Approves More Exempt Chemicals from Controlled List
Published Date: 8/14/2026
Notice
Summary
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Approved Preparations Are Exempted From Specific CSA Sections
If you applied for exempt chemical preparation status between March 1, 2026 and June 30, 2026 and your application was approved, your specific preparation is exempt from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 of the Controlled Substances Act (21 U.S.C. 822-823, 825-829, and 952-954) and from 21 CFR 1301.74, effective as of the date given in your approval letter. The exemption only covers the precise preparation and forms described in the application.
Bulk Exempted Products Limited To In‑House Use
DEA determined that each exempted bulk product listed in this order may only be used in‑house by the manufacturer and may not be distributed for any purpose or transported to other facilities. This restriction applies to bulk quantities to limit diversion risks.
Exemptions Apply Only To Exact Product Descriptions
Any exemption granted applies only to the precise preparation, mixture, form(s), and trade name described in the DEA application. Under 21 CFR 1308.24(h), any change in quantitative or qualitative composition or a change in trade name after the application date requires a new DEA application.
Other CSA/CFR Obligations Still Apply, Including Importer Registration
Even when a preparation is exempt under this order, all other requirements of the Controlled Substances Act and regulations still apply. For example, importers must still register as importers as required by 21 U.S.C. 957.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-19840, Christopher Nadorff, M.D.; Decision and Order
Dr. Christopher Nadorff from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
2026-19842, JT Medical, LLC; Decision and Order
JT Medical, LLC tried to get a DEA registration to handle marijuana but didn’t meet the rules because they couldn’t prove they had a real supply deal or a secure storage cabinet. Since they didn’t respond to the government’s concerns on time, their application was denied. This means JT Medical can’t legally handle marijuana products, and anyone working with them should look for other options.
2026-19839, Jorge J. Figueroa, M.D.; Decision and Order
Dr. Jorge J. Figueroa from New Jersey lost his DEA registration because he was kicked out of Medicare, Medicaid, and other federal health programs. He didn’t ask for a hearing, so the DEA made the decision official. This means he can’t legally handle controlled substances anymore, effective immediately, impacting his medical practice and income.
Previous / Next Documents
Previous: 2026-16664, Meeting of the National Organic Standards Board
The National Organic Standards Board is meeting online from October 27-29, 2026, to decide which substances can be used in organic farming. Farmers, producers, and consumers interested in organic food will be affected by these decisions. You can share your thoughts by October 1, 2026, and join public comment sessions on October 20 and 22—no travel needed and no cost to participate!
Next: 2026-16666, Determination That ANSAID (Flurbiprofen) Tablets, 50 Milligrams and 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that ANSAID (flurbiprofen) tablets, 50 milligrams (mg) and 100 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for flurbiprofen tablets, 50 mg and 100 mg, if all other legal and regulatory requirements are met.